Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced its earnings results on Monday. The biotechnology company reported $0.11 EPS for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.03), Fidelity Earnings reports. Arrowhead Pharmaceuticals had a net margin of 33.28% and a return on equity of 26.27%. The firm had revenue of $43.29 million for the quarter, compared to analyst estimates of $36.97 million.
ARWR stock opened at $67.70 on Wednesday. The business has a 50 day simple moving average of $41.15 and a 200-day simple moving average of $31.08. The firm has a market capitalization of $4.66 billion, a PE ratio of 98.12 and a beta of 1.68. Arrowhead Pharmaceuticals has a 1 year low of $10.41 and a 1 year high of $67.77.
A number of equities analysts have commented on the company. Cantor Fitzgerald reissued a “neutral” rating and set a $50.00 target price (up previously from $24.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, November 19th. Robert W. Baird raised Arrowhead Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the company from $39.00 to $70.00 in a report on Monday. Piper Jaffray Companies reissued an “overweight” rating and set a $72.00 target price (up previously from $54.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday. BidaskClub upgraded Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 9th. Finally, S&P Equity Research restated a “buy” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $59.20.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Recommended Story: Trade Deficit
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.